Financial reports
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
24 Feb 22
10-Q
2021 Q3
Quarterly report
4 Nov 21
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
18 Feb 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
Current reports
8-K/A
Termination of a Material Definitive Agreement
13 Jan 23
8-K
Termination of a Material Definitive Agreement
3 Jan 23
8-K
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
10 Nov 22
8-K
Entry into a Material Definitive Agreement
8 Nov 22
8-K
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
7 Nov 22
8-K
Oyster Point Pharma Reports Second Quarter 2022 Financial Results and Recent Business Highlights
11 Aug 22
8-K
Departure of Directors or Certain Officers
12 Jul 22
8-K
Oyster Point Pharma Announces Operating Expense Streamlining Plan
28 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 22
8-K
Oyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business Highlights
5 May 22
Registration and prospectus
15-12G
Securities registration termination
13 Jan 23
25-NSE
Exchange delisting
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 23
POS AM
Prospectus update (post-effective amendment)
3 Jan 23
SC 14D9/A
Tender offer solicitation (amended)
3 Jan 23
SC TO-T/A
Third party tender offer statement (amended)
3 Jan 23
SC 14D9/A
Tender offer solicitation (amended)
23 Dec 22
Other
EFFECT
Notice of effectiveness
6 Jan 23
EFFECT
Notice of effectiveness
17 Nov 20
CORRESP
Correspondence with SEC
12 Nov 20
UPLOAD
Letter from SEC
10 Nov 20
EFFECT
Notice of effectiveness
15 May 20
CORRESP
Correspondence with SEC
12 May 20
CORRESP
Correspondence with SEC
12 May 20
UPLOAD
Letter from SEC
4 May 20
EFFECT
Notice of effectiveness
31 Oct 19
CERT
Certification of approval for exchange listing
28 Oct 19
Ownership
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 23
SC 13D/A
Versant Venture Capital VI, L.P.
13 Jan 23
SC 13D/A
New Enterprise Associates 14, L.P.
9 Jan 23
SC 13D/A
InvOpps IV US, L.P.
5 Jan 23
4
SACHA LAINOVIC
5 Jan 23
4
Change in insider ownership
4 Jan 23
4
Ali Behbahani
4 Jan 23
4
PATRICK J KERINS
4 Jan 23